Akura Medical has enrolled the first subject in the multi-centre QUADRA-PE trial, which is assessing its flagship Katana thrombectomy system in treating acute pulmonary embolism (PE) patients.

TriStar Centennial Medical Center’s cardiovascular research director Dr Samuel Horr performed the procedures.

The international trial aims to enrol up to 118 subjects with clinically significant acute PE at up to 26 worldwide sites.

The trial’s primary effectiveness endpoints include the composite major adverse events (MAEs) rate within 48 hours post-procedure, and a decrease in the right ventricular/left ventricular (RV/LV) ratio from baseline to 48 hours after the procedure, as evaluated by computed tomography (CT) angiography.

The system includes a low-profile, bi-directional sheath tailored to navigate complex vasculature smoothly, allowing for contrast injection without the need for catheter exchanges.

It features ‘high-velocity’ saline jets designed for clot breaking, regardless of its form, and helps eliminate catheter blockages.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The sensors-equipped system delivers real-time data on pulmonary artery pressure, offering insights into the procedure’s progression.

Katana’s Sentinel Console provides critical information on clot engagement and blood loss, helping physicians make informed decisions and potentially reduce procedural uncertainty.

QUADRA-PE trial co-principal investigator and Columbia University Medical Center interventional cardiologist Sanjum Sethi said: “One of the biggest challenges in thrombectomy procedures for PE is determining when you’ve successfully removed the thrombus entirely, as incomplete removal can lead to suboptimal outcomes.

“The Katana System’s display of real-time pressure data represents a significant advancement, providing physicians with clinically useful insights during the procedure.”

A Shifamed portfolio company, Akura focuses on solutions for venous thromboembolism (VTE). The Katana system is currently in the investigational phase and is not yet available for sale.

In October 2023, the company secured $35m in Series B financing for its mechanical thrombectomy platform.